The role of the primary care physician (PCP) in heart failure management is explored.
This is a video synopsis/summary of a panel discussion involving Robert Groves, MD; Eugene E. Wright Jr, MD; Nancy Albert, PhD, CCNS, CCRN, CHFN, NE-BC, FAHA, FCCM, FHFSA, FAAN; Nihar Desai, MD, MPH; and Kelly Marie Axsom, MD. The panel discusses the respective roles of primary care physicians and specialists in heart failure management. Primary care focuses on prevention through early screening and aggressive treatment to prevent progression. They address risk factors like hypertension, diabetes, and weight. Specialists manage more complex symptomatic patients. However, many primary care doctors are not screening for preclinical stage B heart failure, which can be done with simple blood biomarker tests like BNP (B-type natriuretic peptide) or NT-proBNP (N-terminal pro-B-type natriuretic peptide). The goal is detecting dysfunction before symptoms arise to enable earlier intervention. Consensus guidelines aim to improve education on screening and treatment pathways for primary care. Axsom notes NT-proBNP may be preferred as it is more stable and better for monitoring treatment response. Still, implementation in primary care remains challenging. Overall, primary care should focus on prevention and screening while specialists manage more advanced disease, but knowledge gaps on guidelines need addressing.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
Study Highlights Key RA-ILD Risk Factors, Urges Early Screening
November 20th 2024This recent study highlights key risk factors for rheumatoid arthritis–associated interstitial lung disease (RA-ILD), emphasizing the importance of early screening to improve diagnosis and patient outcomes.
Read More
Why Right Heart Catheterization Confirming PAH Diagnosis May Be Underperformed
November 20th 2024Professional guidelines say that when pulmonary arterial hypertension (PAH) is diagnosed, right heart catheterization should be performed, but a quarter of the time, it isn’t—so investigators set out to discover why.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
New PsA Data Highlight Long-Term Benefits of Bimekizumab
November 19th 2024A trio of abstracts presented at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, bear out the benefits of bimekizumab (Bimzelx; UCB Pharma) for use against active psoriatic arthritis (PsA).
Read More